drugset / Trial / NCT00297401

Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus

NCT00297401 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

Protein kinase C (PKC), an enzyme in the body, has been implicated in the process of diabetic microvascular complications. The purpose of this study will be to evaluate the renal hemodynamic and peripheral vascular effects of PKC inhibition with ruboxistaurin mesylate (an inhibitor of PKC) in patients with Type 1 diabetes mellitus and evidence of early nephropathy. In this pilot study, 21 patients with type 1 diabetes were planned to be randomized to LY333531 or placebo in a 2:1 fashion, after an initial period of testing. After 8 weeks of study drug, patients were retested.

Timeline

Start
2006-03
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruboxistaurin Small molecule 32 mg Oral